Gabriel Etienne
Overview
Explore the profile of Gabriel Etienne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
4120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerineau H, Cayuela J, Dulucq S, Tran Quang V, Tarfi S, Gricourt G, et al.
Am J Hematol
. 2024 Dec;
100(3):507-510.
PMID: 39654506
No abstract available.
2.
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia
Deschamps P, Wacheux M, Gosseye A, Morabito M, Pages A, Lyne A, et al.
J Clin Invest
. 2024 Nov;
134(22).
PMID: 39545419
Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy with limited therapeutic options. Single-cell analysis of clonal architecture demonstrates early clonal dominance with few residual WT hematopoietic stem cells. Circulating...
3.
Efficace F, Mahon F, Richter J, Piciocchi A, Cipriani M, Nicolini F, et al.
Leukemia
. 2024 Jul;
38(8):1722-1730.
PMID: 38987274
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL...
4.
Hochhaus A, Wang J, Kim D, Kim D, Mayer J, Goh Y, et al.
N Engl J Med
. 2024 May;
391(10):885-898.
PMID: 38820078
Background: Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better...
5.
Cortes J, Sasaki K, Kim D, Hughes T, Etienne G, Mauro M, et al.
Leukemia
. 2024 May;
38(7):1522-1533.
PMID: 38755421
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1, which is resistant to most approved adenosine triphosphate-competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability...
6.
Mahon F, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al.
J Clin Oncol
. 2024 Mar;
42(16):1875-1880.
PMID: 38471049
JCO The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable...
7.
Alcazer V, Morisset S, Rea D, Legros L, Dulucq S, Hayette S, et al.
Br J Haematol
. 2024 Feb;
204(4):1536-1539.
PMID: 38323384
No abstract available.
8.
Rea D, Cayssials E, Charbonnier A, Coiteux V, Etienne G, Goldwirt L, et al.
Bull Cancer
. 2023 Dec;
111(1):87-96.
PMID: 38087729
The treatment of chronic myeloid leukemia relies on orally available tyrosine kinase inhibitors targeting the BCR::ABL1 oncoprotein. Bosutinib is a second generation adenosine triphosphate-competitive inhibitor approved for use in frontline...
9.
Nicolini F, Huguet F, Huynh L, Xu C, Bouvier C, Yocolly A, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627189
This retrospective chart review study investigated the clinical burden of adult patients with chronic-phase chronic myeloid leukemia (CP-CML) treated at three centers in France (2006-2021) who failed on two or...
10.
Huguet F, Rea D, Cayssials E, Etienne G, Nicolini F
Expert Rev Hematol
. 2023 Jul;
16(9):633-639.
PMID: 37427999
Introduction: Ponatinib exhibits a high inhibition potency on wild-type and most mutated forms of the kinase, but also a significant cardiovascular toxicity. Improving the efficacy/safety ratio should allow patients to...